Quanterix announces Anthem Blue Cross Blue Shield coverage for LucentAD Complete Alzheimer's blood test
QTRX•Study cited in release
The release also cited a peer-reviewed study reporting diagnostic parity versus an IP-MS method; the multi-analyte algorithm cut indeterminate results about three-fold.
Anthem coverage for LucentAD Complete
Quanterix posted a press release noting Anthem Blue Cross and Blue Shield commercial coverage for LucentAD Complete blood-based Alzheimer’s testing from July 1, 2026.
Coverage applies when medical-necessity criteria are met under LAB.00046: Testing for Biochemical Markers for Alzheimer Disease.
